Sign In
Buy ALNY
$291.22
-6.47 (-2.17%)
At Close: Jun 10, 2026
Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year?
10:46am, Thursday, 17'th Oct 2024
Here is how Alnylam Pharmaceuticals (ALNY) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU
10:36am, Thursday, 17'th Oct 2024
ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR amyloidosis with cardiomyopathy.
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
08:00am, Thursday, 17'th Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter endi
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) t
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
10:51am, Wednesday, 02'nd Oct 2024
Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
10:46am, Tuesday, 01'st Oct 2024
Here is how Alnylam Pharmaceuticals (ALNY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vutris
Alnylam to Webcast TTR Investor Day
08:00am, Thursday, 26'th Sep 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on the
Alnylam Stock Soars 65%: Find Out What's Behind the Gains
07:00am, Thursday, 12'th Sep 2024
Alnylam Pharmaceuticals NASDAQ: ALNY stock price action has been volatile but is uptrending and has gained 100% in the last two years. The uptrend is driven by increasing expectations for market-disru
ALNY Down Despite Positive Data From Heart Disease Drug Study
03:01pm, Monday, 02'nd Sep 2024
Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy.
DALLAS--(BUSINESS WIRE)--Steward Health Care (“Steward”), the country's largest physician-led, minority-owned, integrated health care system, announced today it has reached an agreement in princip
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
09:51am, Friday, 30'th Aug 2024
Friday, Alnylam Pharmaceuticals Inc. ALNY stock is trading lower after the company shared detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy (ATTR-
Alnylam shares slide after heart drug data fails to impress investors
08:37am, Friday, 30'th Aug 2024
Alnylam Pharmaceuticals' shares fell nearly 11% before the bell on Friday, after data for its closely watched heart drug fell short of heightened investor expectations.
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
11:25am, Friday, 23'rd Aug 2024
Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.
The 3 Best Gene Editing Stocks to Buy in August 2024
09:00am, Wednesday, 07'th Aug 2024
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030.
